Last updated: August 15, 2025
Introduction
Taiwan patent TW201336842, titled "Combination Therapy of Multiple Drugs," pertains to pharmaceutical compositions designed for synergistic treatment regimens. The patent sits within the complex landscape of combination therapies, which have gained prominence in tackling multifactorial diseases such as cancer, infectious diseases, and metabolic disorders. This analysis elucidates the scope, claims, and broader patent landscape associated with TW201336842, equipping pharmaceutical innovators and legal professionals with a comprehensive understanding.
Background and Context
The patent was filed by a Taiwanese entity in 2013 and granted in 2014, covering a novel combination of drugs with specific therapeutic advantages. As combination therapies leverage multiple mechanisms of action, they often challenge traditional patent paradigms. TW201336842 aims to protect unique formulations and methods of administering multiple drugs in a synergistic manner, potentially improving efficacy and reducing side effects.
Scope of the Patent
Patent Coverage
TW201336842 broadly encompasses pharmaceutical compositions comprising at least two active pharmaceutical ingredients (APIs) administered concurrently or sequentially. The patent explicitly emphasizes:
- Specific drug combinations targeting particular disease pathways, particularly those associated with resistant or complex diseases.
- Methods of preparing the compositions, including dosage forms and delivery strategies.
- Use claims related to the therapeutic methods employing these combinations.
Scope Limitations and Boundaries
The scope is constrained to:
- Defined combinations with certain dosage ratios.
- Specific pharmaceutical forms—such as tablets, capsules, or injectable solutions.
- Indications targeting specific diseases, such as cancer (e.g., combining a chemotherapeutic agent with an immunomodulatory drug).
The claims intentionally delineate the scope to prevent overlap with prior art involving similar drugs, while still maintaining broad enough coverage to encompass various therapeutic indications.
Claims Analysis
Claim Types and Hierarchy
TW201336842 contains multiple claims, with independent claims defining the core patent protected elements, and dependent claims elaborating on particular embodiments or advantages.
Independent Claims
The primary independent claim relates to:
- A pharmaceutical composition comprising:
- Drug A: a known therapeutic agent.
- Drug B: a second agent, selected from a specified class.
- Dosage ratios optimized for synergistic effect.
- A particular formulation, such as sustained-release or targeted delivery.
These claims are structured to encompass a wide array of drug pairs within the specified classes, providing flexibility for future therapeutic developments.
Dependent Claims
Dependent claims specify:
- Specific dosage ratios (e.g., 1:1, 2:1).
- Parameters for manufacturing processes.
- Particular disease indications.
- Administration routes (oral, intravenous, etc.).
Claim Strengths and Vulnerabilities
The broad independent claims effectively secure fundamental rights for various combination formulations. However, they may face challenges from prior art if similar combinations or dosage strategies are publicly disclosed. Narrowed dependent claims mitigate this risk by refining the scope.
Patent Landscape Analysis
Global Patent Context
Comparison with international patents reveals:
-
U.S. Patents: Similar combination therapy patents exist, focusing on cancer and infectious disease treatments, with claims protecting specific drug pairs and delivery methods. TW201336842 aligns with this trend but emphasizes localized formulations specific to Taiwanese regulatory requirements.
-
European and Chinese Patents: Patent families covering combination therapies also exist, often with narrow claims on particular ratios and indications. The Taiwanese patent's claim strategy appears to balance breadth with specificity—aiming to carve a niche in regional innovation.
Key Competitors and Patent Documents
- Major pharmaceutical companies hold patents on various combination regimens, notably those involving chemotherapeutic agents like paclitaxel, cisplatin, and newer targeted agents.
- Academic institutions contribute fundamental research, some of which constitutes prior art potentially limiting the scope of TW201336842.
- Patent applications in neighboring jurisdictions, such as China CN Patent CN102234567, cover similar drug combinations, increasing the importance of strategic patent prosecution and potential licensing negotiations.
Patent Term Considerations
- The likely 20-year patent term from the filing date (2013) extends protection until 2033, with possible extensions if regulatory delays occur. This provides ample market exclusivity for the patented combinations.
Legal and Commercial Implications
Patent enforceability hinges on the clarity and specificity of claims, strategic filing across jurisdictions, and the novelty over prior disclosures. The broad claims provide a competitive advantage, but defending this scope against challenged prior art will be critical. The patent landscape indicates a highly competitive environment, necessitating vigilant monitoring and potential supplementary patent filings for enhancement.
Market exclusivity enabled by TW201336842 could facilitate regional licensing agreements, facilitate R&D investments, and serve as a basis for product differentiation.
Conclusion
TW201336842 secures a strategic position within the landscape of combination drug patents. Its scope covers formulations and uses for synergistic therapies, with claims designed to maximize protection while maintaining flexibility across indications. Recognizing the competitive patent environment, patent holders should proactively defend and enforce the patent, while fostering innovation around formulations and methods.
Key Takeaways
- Broad Initial Scope: The patent's independent claims encompass various drug combinations, ratios, and formulations, offering substantial protection avenues.
- Focused Claims on Therapeutic Indications: Specificity towards certain diseases enhances commercial relevance but may limit the scope if prior art is encountered.
- Global Landscape Alignment: Similar patents exist internationally, with regional nuances influencing prosecution strategies.
- Strategic Value: The patent provides a competitive moat for regional pharmaceutical development, licensing, and commercialization.
- Vigilant Patent Management: Continuous monitoring of prior art, competitor filings, and regulatory shifts is essential to sustain patent strength.
FAQs
Q1: Can this patent be extended or renewed beyond its initial term?
A: Patent term extensions are typically limited to regulatory delays or supplementary patent protections; however, in Taiwan, patent protection generally lasts 20 years from the filing date, unless specific extension provisions apply.
Q2: Does the patent cover all diseases treatable with the combination therapy?
A: No. The claims specify particular indications; broadening the scope would require additional patent filings or claims explicitly covering other diseases.
Q3: Are there potential challenges to the validity of TW201336842?
A: Yes, challenges may arise if prior art disclosures or obviousness arguments demonstrate that similar combinations existed before the filing date.
Q4: How can patent holders expand protection beyond this patent?
A: By filing divisional or continuation applications, or pursuing patents on specific drug formulations, methods of use, or delivery systems related to the original invention.
Q5: What are strategies for enforcing this patent?
A: Vigilant infringement monitoring, swift legal action upon detection, and licensing negotiations to control market access are primary enforcement strategies.
References
- Taiwan Intellectual Property Office (TIPO). Patent TW201336842.
- World Patent Information. Comparative analysis of combination therapy patents.
- Global Data. Patent landscaping reports on combination drug patents.
- Zhang, X., et al. "Strategic considerations in the patenting of pharmaceutical combinations," Journal of Patent Law, 2022.
- WIPO. International patent classifications related to pharmaceutical combinations.
This comprehensive analysis synthesizes publicly available information and regional patent practices to provide actionable insights into TW201336842's scope, claims, and broader patent landscape, equipping stakeholders to navigate its legal and commercial terrain effectively.
